| 1. |
- Guaran, Valeria, et al.
(författare)
-
Association between idiopathic hearing loss and mitochondrial DNA mutations : a study on 169 hearing-impaired subjects
- 2013
-
Ingår i: International Journal of Molecular Medicine. - Athen : Spandidos Publications. - 1107-3756 .- 1791-244X. ; 32:4, s. 785-794
-
Tidskriftsartikel (refereegranskat)abstract
- Mutations in mitochondrial DNA (mtDNA) have been shown to be an important cause of sensorineural hearing loss (SNHL). In this study, we performed a clinical and genetic analysis of 169 hearing-impaired patients and some of their relatives suffering from idiopathic SNHL, both familial and sporadic. The analysis of four fragments of their mtDNA identified several polymorphisms, the well known pathogenic mutation, A1555G, and some novel mutations in different genes, implying changes in the aminoacidic sequence. A novel sporadic mutation in 12S rRNA (MT-RNR1), not previously reported in the literature, was found in a case of possible aminoglycoside-induced progressive deafness.
|
|
| 2. |
- Simoni, Edi, et al.
(författare)
-
Biocompatibility of glycerol monooleate nanoparticles as tested on inner ear cells
- 2019
-
Ingår i: International Journal of Pharmaceutics. - : Elsevier B.V.. - 0378-5173 .- 1873-3476. ; 572
-
Tidskriftsartikel (refereegranskat)abstract
- Sensorineural hearing loss due to aging, noise exposure, trauma or drug ototoxicity is irreversible because cochlear hair cells and neurons cannot regenerate. Recently, therapeutic strategies involving nanoparticles have been developed as innovative drug delivery systems. Thermodynamically stable liquid crystalline nanoparticles based on the polar lipid glycerol monooleate (GMO NP, cubosomes), nontoxic and able to encapsulate both hydrophilic and hydrophobic compounds, were produced and tested for biocompatibility in an immortalized Organ of Corti derived cell line (OC-k3), through cell viability and cytomorphological assays, and Western blot expression profiles of apoptotic markers. Overall, the GMO NP were biocompatible in OC-k3 at the doses and time tested, supporting previous data obtained in a neuronal cell line (PC12). The results encourage further tests on GMO NP-mediated drug release with improved target specificity and could be useful to develop innovative therapies against sensorineural hearing loss.
|
|
| 3. |
- Valente, Filippo, et al.
(författare)
-
Evaluation of toxicity of glycerol monooleate nanoparticles on PC12 cell line.
- 2018
-
Ingår i: International Journal of Pharmaceutics. - : Elsevier BV. - 0378-5173 .- 1873-3476. ; 539:1-2, s. 23-30
-
Tidskriftsartikel (refereegranskat)abstract
- An innovative approach to improve drug delivery is the use of glycerol monooleate nanoparticles. Numerous studies describe their high versatility, low toxicity and ability to carry relatively high loads of conjugated compounds including scarcely soluble ones, providing sustained drug release and increasing drug diffusion and half-life. Despite a growing interest in their potential use for therapeutic applications, there are surprisingly few literature data concerning the toxic effects of these nanoparticles at high concentrations in vitro and in vivo, and their effects on cell metabolism. We produced and characterized from a physical-chemical point of view glycerol monooleate nanoparticles and tested them on the PC12 cell line, a rat model of neuronal differentiation. The toxicity of these nanoparticles was evaluated by molecular methods on cell viability, cell cycle, nanoparticle uptake and induction of apoptosis. The results showed that glycerol monooleate nanoparticles up to 100 μg/mL had no toxic effects on PC12 cells, did not induce significant changes in the cell cycle nor cause apoptosis. The nanoparticles entered PC12 cells 8 h after treatment, successfully delivering the conjugate compound inside cells. Overall, glycerol monooleate nanoparticles did not exhibit significant toxicity on PC12 cell line in concentrations up to 100 µg/mL, supporting their therapeutic use as drug delivery systems.
|
|
| 4. |
- Ye, Fei, et al.
(författare)
-
Uniform mesoporous silica coated iron oxide nanoparticles as a highly efficient, nontoxic MRI T 2 contrast agent with tunable proton relaxivities
- 2012
-
Ingår i: Contrast Media & Molecular Imaging. - : Wiley. - 1555-4309 .- 1555-4317. ; 7:5, s. 460-468
-
Tidskriftsartikel (refereegranskat)abstract
- Monodisperse mesoporous silica (mSiO 2) coated superparamagnetic iron oxide (Fe 3O 4@mSiO 2) nanoparticles (NPs) have been developed as a potential magnetic resonance imaging (MRI) T 2 contrast agent. To evaluate the effect of surface coating on MRI contrast efficiency, we examined the proton relaxivities of Fe 3O 4@mSiO 2 NPs with different coating thicknesses. It was found that the mSiO 2 coating has a significant impact on the efficiency of Fe 3O 4 NPs for MRI contrast enhancement. The efficiency increases with the thickness of mSiO 2 coating and is much higher than that of the commercial contrast agents. Nuclear magnetic resonance (NMR) relaxometry of Fe 3O 4@mSiO 2 further revealed that mSiO 2 coating is partially permeable to water molecules and therefore induces the decrease of longitudinal relaxivity, r 1. Biocompatibility evaluation of various sized (ca. 35-95 nm) Fe 3O 4@mSiO 2 NPs was tested on OC-k3 cells and the result showed that these particles have no negative impact on cell viability. The enhanced MRI efficiency of Fe 3O 4@mSiO 2 highlights these core-shell particles as highly efficient T 2 contrast agents with high biocompatibility.
|
|
